Copper Facing an Onslaught of Demand



Ford’s Announcement is Another Reason for Copper Investors to Smile

 

Ford Motor is gaining on Tesla in the hearts of EV and ESG investors. The company gave both fans and investors in the growth of electric vehicle technology, along with those supporting green energy acceptance, a reason to cheer this week. The iconic company, known for its contribution to manufacturing technology one hundred years ago (1928), which made automobiles available to average families, may again make history by ushering in an era where electric Mustangs, Explorers, and even Broncos are within the price range of the American middle class.  An announcement by Ford on May 26 committed the company to spend $30 billion on electric vehicle manufacturing by 2025 and for 40 percent of its global fleet to be all-electric by 2030.

The EV movement had already shifted into high gear before the announcement. And, with the strongest economies of the world now aligned in supporting carbon reduction policies, ie: electrification, a revolution has begun. As with other dramatic historical shifts in technology, investing in the components or industries that produce the goods to make the components is an ordinarily lower risk than betting on any one car company (final product).

 

Copper Components

EV growth has brought a focus on demand for the elements used to produce batteries, such as lithium and cobalt. The focus should also be on how the onslaught of demand for copper will be filled.  There are many competing tech revolutions increasing the demand for the metal. New needs for copper are coming from the growth of solar and wind energy, along with EVs and EV charging stations. As it relates to just cars, here’s how just one car changes demand. An average gasoline-powered car uses about 44lbs of copper, mainly as wiring. A hybrid car uses about 88lbs, and a fully electric car uses roughly 176lbs of the metal. As part of the increased demand, add about 45lbs for each charging point.

In all, 5 times more copper than a conventional gas-powered car is needed. Copper has the best conductivity of any non-precious metal and is being called upon to electrify the green renewable energy revolution

 

How to Get Copper Exposure with Stocks

When the price of copper rises, copper mining companies benefit from production without increasing their costs. This makes buying miners a strategy worth considering. Yesterday Noble Capital Markets released a research note on Chakana Copper Corp. (CHKKF) and (PERU:CA). The report includes the latest company results, the analyst’s views, and price targets. Also available on Channelchek related to CHKKF is the average daily volume of shares traded which is important to gauge liquidity.  Up to the minute, data can also be found on Channelchek for other copper mining companies.  The domestic miner Nevada Copper Corp. (NEVDF) is a U.S.-based mining company currently trading at $0.21 which is in the lower quartile of its 52-week trading range. Western Copper & Gold Corp (WRN) is a Canada-based exploration-stage company. Its engaged in the acquisition, exploration, and future development of resource properties. WRN is currently trading near the top of its 52-week range at $2.61.

Other copper mining candidates can be found at Channelchek.com under the “Company Data” section.

 

Take-Away

There’s a revolution going on with a move toward putting more electric cars on the road. Although Tesla tends to grab the spotlight, there are many other new car companies that are involved.  Meanwhile, traditional auto manufacturers all have goals to increase their EV offerings. Coupled with what is going on in wind and solar, which also increases demand for copper, investors may want to look toward investing in what now appears inevitable.

 

Your Personal Data is the Currency of the Digital Age

Repurposing Power Plants for Crypto Mining



Chakana Copper C-Suite Interview

Palladium One Mining C-Suite Interview

 

Sources:

https://tradingeconomics.com/commodity/copper

https://www.barrons.com/articles/ford-motor-stock-ev-spending-investor-day-51622041264

Euroseas Ltd. (ESEA) – Longer Charters at Higher Rates Drive Upgrade to Outperform

Thursday, May 27, 2021

Euroseas Ltd. (ESEA)
Longer Charters at Higher Rates Drive Upgrade to Outperform

Euroseas Ltd. provides ocean-going transportation services worldwide. The company owns and operates containerships that transport dry and refrigerated containerized cargoes, including manufactured products and perishables; and drybulk carriers that transport iron ore, coal, grains, bauxite, phosphate, and fertilizers. As of March 31, 2017, it had a fleet of seven containerships; and six drybulk carriers, including three Panamax drybulk carriers, one Handymax drybulk carrier, one Kamsarmax drybulk carrier, and one Ultramax drybulk carrier. The company was founded in 2005 and is based in Maroussi, Greece.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Adjusted 1Q2021 EBITDA of $5.7 million in line with expectations with higher TCE rates offsetting higher opex. Reported adjusted EBITDA was $5.6 million. TCE revenue of $14.7 million increased from $12.5 million in 4Q2020 due to a $1,637 move up in TCE rates to $12,134/day from $10,497/day, higher shipping days of 1,219 versus 1,190 in 4Q2020 and lower idle days of 41 versus 138 in 4Q2020.

    Fine-tuning 2021 EBITDA estimate to reflect to reflect 1Q2021 results and updated forward cover.  We are moving 2021 EBITDA to $40.6 million based on TCE rates of $16.7k/day from $37.5 million based on TCE rates of $16.2k/day. Visibility is very high with 89% of available 2021 days booked at $15.2k/day due to longer charters signed at higher TCE rates …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

QuickChek – May 27, 2021



Great Lakes Announces Participation in the Noble Capital Markets Virtual Road Show

Great Lakes Dredge & Dock announced their participation in Noble Capital Markets Virtual Road Show Series, presented by Channelchek, scheduled for June 2, 2021

Research, News & Market Data on Great Lakes Dredge & Dock

Watch recent presentation from NobleCon17



Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™

Ocugen confirmed its plan to submit its Emergency Use Authorization (EUA) application for COVAXIN to the U.S. Food & Drug Administration (FDA) in June

Research, News & Market Data on Ocugen

Watch recent presentation from NobleCon17



ProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer

ProMIS Neurosciences announced the appointment of Dr. David Wishart, Distinguished University Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta, as Chief Physics Officer at ProMIS

Research, News & Market Data on ProMIS Neurosciences



PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance

PDS Biotechnology announced a strategic partnership to share information about emerging treatment options with clinicians and patients battling HPV-attributed head and neck cancer

Research, News & Market Data on PDS Biotechnology

Stay up to date. Follow us:

Palladium One Mining Inc. (NKORF)(PDM:CA) – Haukiaho Drill Results Highlight Significant Potential to Expand Resources

Thursday, May 27, 2021

Palladium One Mining Inc. (NKORF)(PDM:CA)
Haukiaho Drill Results Highlight Significant Potential to Expand Resources

Palladium One Mining Inc is a palladium dominant, PGE, nickel, copper exploration and development company. Its assets consist of the Lantinen Koillismaa and Kostonjarvi PGE-Cu-Ni projects, located in north-central Finland and the Tyko Ni-Cu-PGE and Disraeli PGE-Ni-Cu properties in Ontario, Canada. LK is targeting disseminated sulphide along 38 kilometers of favorable basal contact. The KS project is targeting massive sulphide within a 20,000-hectare land package covering a regional scale gravity and magnetic geophysical anomaly. Tyko is a 13,000-hectare project targeting disseminated and massive sulphide in a highly metamorphosed Archean terrain. Disraeli is a 2,500-hectare project targeting PGE-rich disseminated and massive sulphide in a highly productive Proterozoic mid-continent rift.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Haukiaho drill results. Palladium One released results for 7 of 12 holes drilled at the Haukiaho Trend roughly 20 kilometers south of Kaukua South. Results returned significant widths and grades, including 72.2 meters at 1.79 grams of palladium equivalent per tonne, and expanded mineralization to the east of and higher grade areas within the known historic Haukiaho resource area.

    Haukiaho technical report expected in the third quarter.  The drill program was intended to provide sufficient drill density to prepare a NI 43-101 resource estimate for Haukiaho which management anticipates completing in the third quarter of 2021. In 2013, Finore Mining Inc. completed a non-pit constrained NI 43-101 historic resource with 23.2 million tonnes of ore with an average grade of 1.51 …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Casual Dining and Fast Serve to Benefit from Back-to-Work



As People Make it Back to the Office, Restaurants See More Traffic

 

Restaurants Welcome Back to Work Traffic

The 2020 pandemic beat up many industries while causing others to rocket. Stock market investors endured sharp selloffs and, in many sectors, rapid recovery. Industries including hospitality and food were among the hardest hit as many restaurants saw their stocks crash during the Covid era. While some restaurants did what they could with either complete lockdowns, or a substantially reduced dining room capacity, and a low customer appetite for dining in, their business was still well-off the normal pace.

To make matters more trying for restaurants, the businesses in their neighborhood had employees working remotely  grocery store sales were up; lunchtime restaurant traffic was limited.  According to Sentieo, publicly traded restaurant chains saw an increase in the price of only 4% in all of 2020 as compared to an 18% total return on the S&P 500.

In 2021, things look much better for restaurants. As many states, counties, and towns began to ease the previous restrictions and capacity limits, restaurant stocks began to climb back up. By some measures, restaurant stocks already have a year-on-year increase of 51.7%. Clearly, we’re getting past the turning point of the post-Covid era. Can we expect more growth in the sector?

 

“We’re absolutely seeing an increase in lunchtime traffic as well as maintaining delivery and to-go
business. We’re working on all cylinders right now.”
– Andy Wiederhorn, CEO, FAT Brands

 

People are Doing What they Couldn’t do Before

Now at the tail-end of the Covid 19 era, authorities in the U.S. and many countries have begun to ease restrictions. People now do things they previously could not. For instance, they can now take their families to dinner, explore theme parks and spend in ways they were prevented from during the lockdown.

Earlier this year, investors began moving into recreational stocks like Disney (DIS). The result, between January 27 and March 8, DIS saw a 24% increase in market value before retreating. Full-service restaurants saw a similar spike as investors anticipated full dining rooms. People who had been restricting themselves to their homes now were expected to do things they were not.

Andy Wiederhorn, CEO of FAT Brands (FAT), responded to a listener question last week on lunchtime traffic. He was the guest at a Channelchek sponsored Virtual Roadshow.  Wiederhorn responded, “some restaurants are at 120% of sales pre-covid.”  Fat Brands is a restaurant franchising company that owns  the Fatburger, Johnny Rockets, Buffalo’s Cafe, Buffalo’s Express, Hurricane Grill & Wings, Yalla Mediterranean, Ponderosa, Bonanza, and Elevation Burger brands. As it relates to traffic, Mr. Wiederhorn added, “sales over the past month are reaching all-time highs with some of the brands.” He responded more directly, “ We’re absolutely seeing an increase in lunchtime traffic as well as maintaining delivery and to-go business. We’re working on all cylinders right now.”

 

Recreational Dining vs. Regular Dining Out

Employers and government workers worldwide are starting to call back their staff members. This is coming as many governments and business organizations look to resume full onsite operations by late June. This is welcome by most. According to a study by Morning Consult, 65% of remote workers are ready to return to their offices to start resume working as they did before.

This adds to the good news for restaurants that relied in large part on local businesses adding to their lunchtime customers. It takes the remote workers who were preparing lunch in their kitchen and places them back in the running to a fast service restaurant.

Throughout the COVID 19 crisis, fast food and partial service food outlets struggled to survive. Some of them were already set up for take-outs. However, there have already been large spikes in companies that cater to workers stopping in for lunch. For instance, Mac Donald’s stock is up by 11%, just as the entire market surges around the same percentage. We expect that with a massive return to work as we hope soon, the dining rooms of these restaurants will see more large crowds. This will, in turn, boost their revenues massively and improve the market in general.

 

Suggested Reading:

Space as a Lucrative Investment Space

FAT Brands Virtual Roadshow replay (May 2021)



Cannabis Customers Served by the “Ice Cream Truck” Delivery Model

Toilet Paper Sales Unravel as People are Flush with Paper Goods

 

Sources:

https://morningconsult.com/return-to-work/

https://channelchek.vercel.app/channelcast-detail/228

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

Great Lakes Announces Participation in the Noble Capital Markets Virtual Road Show


Great Lakes Announces Participation in the Noble Capital Markets Virtual Road Show

 

HOUSTON, May 26, 2021 (GLOBE NEWSWIRE) — Great Lakes Dredge & Dock Corporation (“Great Lakes”) (NASDAQ: GLDD), the largest provider of dredging services in the United States announced their participation in Noble Capital Markets Virtual Road Show Series, presented by Channelchek, scheduled for June 2, 2021.

The virtual road show will feature a corporate presentation from Great Lakes Dredge & Dock Corporation’s President and Chief Executive Officer Lasse Petterson and Chief Financial Officer Mark Marinko, followed by a Q&A session proctored by Noble Senior Research Analyst Poe Fratt, featuring questions submitted by the audience.

The live broadcast of the virtual road show is scheduled for Wednesday, June 2, 2021, at 1 PM EDT. Registration is free and open to all investors, at any level. Register Here. Noble’s research, as well as news and advanced market data on Great Lakes is available on Channelchek.

The Company

Great Lakes Dredge & Dock Corporation (“Great Lakes” or the “Company”) is the largest provider of dredging services in the United States. In addition, the Company has a long history of performing significant international projects. The Company employs experienced civil, ocean and mechanical engineering staff in its estimating, production and project management functions. In its over 131-year history, the Company has never failed to complete a marine project. Great Lakes owns and operates the largest and most diverse fleet in the U.S. dredging industry, comprising over 200 specialized vessels. Great Lakes has a disciplined training program for engineers that ensures experienced-based performance as they advance through Company operations. The Company’s Incident-and Injury-Free® (IIF®) safety management program is integrated into all aspects of the Company’s culture. The Company’s commitment to the IIF® culture promotes a work environment where employee safety is paramount.

Noble Capital Markets

Noble Capital Markets, Inc. was incorporated in 1984 as a full-service SEC / FINRA registered broker-dealer, dedicated exclusively to serving underfollowed small / microcap companies through investment banking, wealth management, trading & execution, and equity research activities. Over the past 36 years, Noble has raised billions of dollars for these companies and published more than 45,000 equity research reports.
www.noblecapitalmarkets.com email: contact@noblecapitalmarkets.com

Channelchek

Channelchek (.com) is a comprehensive investor-centric portal – featuring more than 6,000 emerging growth companies – that provides advanced market data, independent research, balanced news, video webcasts, exclusive c-suite interviews, and access to virtual road shows. The site is available to the public at every level without cost or obligation. Research on Channelchek is provided by Noble Capital Markets, Inc., an SEC/FINRA registered broker-dealer since 1984.
channelchek.vercel.app email: contact@channelchek.vercel.app

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking” statements as defined in Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”), the Private Securities Litigation Reform Act of 1995 (the “PSLRA”) or in releases made by the Securities and Exchange Commission (the “SEC”), all as may be amended from time to time. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of Great Lakes and its subsidiaries, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements that are not historical fact are forward-looking statements. These cautionary statements are being made pursuant to the Exchange Act and the PSLRA with the intention of obtaining the benefits of the “safe harbor” provisions of such laws. Great Lakes cautions investors that any forward-looking statements made by Great Lakes are not guarantees or indicative of future events.

Although Great Lakes believes that its plans, intentions and expectations reflected in this press release are reasonable, actual events could differ materially. The forward-looking statements contained in this press release are made only as of the date hereof and Great Lakes does not have or undertake any obligation to update or revise any forward-looking statements whether as a result of new information, subsequent events or otherwise, unless otherwise required by law.

For further information contact:
Tina Baginskis
Director, Investor Relations
630-574-3024

Allegiant Gold Allegiant Gold Ltd (AUXXF)(AUAU:CA) – High-Grade Drill Results Could Be a Game Changer for Eastside

Thursday, May 27, 2021

Allegiant Gold

Allegiant Gold Ltd (AUXXF)(AUAU:CA)
High-Grade Drill Results Could Be a Game Changer for Eastside

Allegiant Gold Ltd is a gold exploration company. Its project profile consists of Bolo, Browns Canyon, Clara Moro, Four Metals, Monitor Hills, Red Hills, Silver Dome, West Goldfield, White Horse Flats, Mogollon, Eastside, Dutch Flat, and others.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Drill results from the Original Pit Zone (OPZ). Allegiant released results from its 9-hole drill program, representing 3,673 meters of drilling, at the Original Pit Zone at its Eastside project in Nevada. Strong gold intercepts were reported for Holes 239, 243, 244 and 245. Mineralization was encountered in 7 of the 9 holes. Hole 243, a 100-meter step-out from the closest hole in the OPZ, included 2.55 grams of gold per tonne over 147.8 meters and 3.17 grams of gold per tonne over 117.3 meters. Hole 239 included 111.3 meters of 1.45 grams of gold per tonne, including 3.1 meters of 39 grams of gold per tonne at the bottom of the hole.

    More drilling at the OPZ may be warranted.  While the Eastside project is generally conceptualized as a low-grade, bulk tonnage open pit mining scenario, the impressive grades may signal a game-changer for project economics. While there are significant opportunities to continue to develop the original pit zone by expanding the permitted area, recent results indicate more drilling may be warranted …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

ProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer


ProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer

 

TORONTO, Ontario and CAMBRIDGE, Mass.—May 27, 2021—ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of  Dr. David Wishart, Distinguished University Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta, as Chief Physics Officer at ProMIS. Dr. Wishart has been  one of the world’s most highly cited scientists for each of the past seven years and brings more than three decades in protein folding and misfolding research to ProMIS, creating industry-leading depth in this area of therapeutic development for neurodegenerative and other diseases. 

“Over the past half year as a member of the ProMIS scientific advisory board (SAB) I have participated in the ProMIS weekly R&D meetings and have come to appreciate the outstanding quality of the ProMIS scientific program and team led by Dr. Neil Cashman. With my appointment as Chief Physics Officer I now look forward to offering my experience and expertise in the field of protein misfolding to the ProMIS team, and in particular to continued expansion of the ProMIS technology platform which is uniquely capable of identifying the sequence and shape (conformation) of novel binding targets on misfolded proteins implicated in the development of neurodegenerative diseases such as Alzheimer’s, Parkinson’s and ALS.”

“ProMIS has leveraged its industry leading technology platform to create a portfolio of antibody, intrabody and vaccine candidates that are highly selective for the misfolded protein aggregates driving pathogenesis,” stated Dr. Neil Cashman, ProMIS Chief Scientific Officer (CSO).  “As Chief Physics Officer, Dr. Wishart will play a pivotal role to further develop and expand the application of our proprietary platform to the biology of additional misfolded protein diseases.  I would also like to take this opportunity to sincerely thank Dr. Steven Plotkin for his outstanding prior service to the company as the ProMIS Chief Physics Officer since its inception.”

“ProMIS’s unique capability is our unrivalled antibody discovery platform, and Dr. Wishart has already added immeasurably to that capability,” said Executive Chairman Eugene Williams.  “IBM’s quantum computing group predicted last year that within five years (i.e., by 2025) quantum computing will enable ‘developing novel biologic products based on protein folding predictions.’  ProMIS has already demonstrated that capability for years, in part by focusing on the narrower problem of predicting conformational epitopes exposed only on pathogenic, mis-folded proteins, but also by collaborating with extraordinarily talented scientists like Dr. Wishart and his team.”

About Dr. David Wishart

Dr. Wishart has been studying protein folding and misfolding for more than 30 years using a combination of computational and experimental approaches. These experimental approaches include NMR spectroscopy, circular dichroism, fluorescence spectroscopy, electron microscopy, protein engineering and molecular biology. The computational methods include molecular dynamics, agent-based modeling, bioinformatics and machine learning. Over the course of his career, Dr. Wishart has published more than 430 scientific papers, which have been cited more than 78,000 times, covering many areas of protein science including structural biology, protein metabolism and computational biochemistry. He has been with the University of Alberta since 1995 and is currently a Distinguished University Professor in the Departments of Biological Sciences and Computing Science. He also holds adjunct appointments with the Faculty of Pharmaceutical Sciences and the Department of Pathology and Laboratory Medicine.  

Dr. Wishart has been awarded research grants totaling more than $130 million from a number of funding agencies. He has also led or directed a number of core facilities and centers and currently co-directs The Metabolomics Innovation Centre (TMIC), Canada’s national metabolomics laboratory. Dr. Wishart held the Bristol-Myers Squibb Research Chair in Pharmaceutical Sciences from 1995-2005, received the Astra-Zeneca-CFPS Young Investigator Prize in 2001, was awarded a Lifetime Honorary Fellowship by the Metabolomics Society in 2014 and was elected as a Fellow of the Royal Society of Canada in 2017. 

About ProMIS Neurosciences

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates—to predict novel targets, known as Disease Specific Epitopes, on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

 

For further information about ProMIS Neurosciences, please consult the Company’s website at:  www.promisneurosciences.com

Follow us on Twitter

Like us on LinkedIn

 

For Investor Relations please contact:

Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate COVAXIN


Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™

 

  • Active discussions with FDA related to COVAXIN initiated late last year
  • Master file submitted to FDA on March 26, 2021; awaiting feedback from FDA

MALVERN, Pa., May 26, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today confirmed its plan to submit its Emergency Use Authorization (EUA) application for COVAXIN to the U.S. Food & Drug Administration (FDA) in June.

“Since we have been in discussions with the FDA since late last year, we do not believe that the FDA’s recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for COVAXIN as planned, which is currently in process and which we expect to submit to the FDA in June. We believe that the FDA’s new guidance confirms that Ocugen continues to meet all criteria for submission of an EUA. Once the EUA application has been submitted, Ocugen intends to commence pre-biologics license application (BLA) discussions with the FDA,” said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen.

“FDA’s guidance refers specifically to vaccines based on the spike protein. COVAXIN is a unique yet traditional vaccine using an inactivated version of the whole virus with a novel adjuvant that provides a broadly protective immune response beyond the spike protein, offering potential effectiveness against multiple existing and emerging variants and reducing the possibility of mutant virus escape,” said Dr. Bruce Forrest, Acting Chief Medical Officer and member of the vaccine scientific advisory board of Ocugen.

About COVAXIN

COVAXIN, India’s COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). COVAXIN is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses supplied. Based on a traditional vaccine platform that has a long-established safety profile, COVAXIN continues to show strong results in all the studies conducted to date including a vaccine efficacy rate of 78% overall efficacy and 100% in severe COVID-19 disease, including hospitalizations, in second interim results of Bharat Biotech’s Phase 3 clinical trial.

In addition to generating strong immune response against multiple antigens, COVAXIN has been shown to generate memory T cell responses, for its multiple epitopes, indicating longevity and a rapid antibody response to future infections. With published data demonstrating a safety profile superior to published safety data from separate studies for several other vaccines, COVAXIN is packaged in multi-dose vials that can be stored at 2-8?C.

COVAXIN studies show potential effectiveness against three key variants of SARS-CoV-2. Scientists at the Indian Council of Medical Research (ICMR)-National Institute of Virology, using an in-vitro plaque reduction neutralization assay, have found that COVAXIN-vaccinated sera effectively neutralized the Brazil variant of SARS-CoV-2, B.1.128.2, the UK variant, B.1.1.7, as well as the Indian double mutant variant, B.1.617. These studies suggest that COVAXIN vaccination may be effective against multiple SARS-CoV-2 variants.

About Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data (including the Phase 3 interim data referred to in this press release), including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech’s clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether the U.S. Food and Drug Administration (FDA) will be satisfied with the design of and results from preclinical and clinical studies of COVAXIN, which have been conducted by Bharat Biotech in India; whether and when any biologics license and/or emergency use authorization applications may be filed in the United States for COVAXIN; whether and when any such applications may be approved by the FDA; decisions by the FDA impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXIN in the United States, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ocugen, Inc.
Sanjay Subramanian
CFO and Head of Corp. Dev.
IR@Ocugen.com

Media Contact:
LaVoieHealthScience
Lisa DeScenza
ldescenza@lavoiehealthscience.com
+1 9783955970 

Virtual Roadshow with FAT Brands (FAT) CEO Andy Wiederhorn


Great Lakes Dredge & Dock CFO Mark Marinko makes a formal corporate presentation. Afterwards, he is joined by Noble Capital Markets Senior Research Analyst Poe Fratt for a Q & A session featuring questions asked by the live audience throughout the event.

Research, News, and Advanced Market Data on FAT


Information on upcoming live virtual roadshows

About FAT (Fresh. Authentic. Tasty.) Brands

FAT Brands (NASDAQ: FAT) is a leading global franchising company that strategically acquires, markets and develops fast casual and casual dining restaurant concepts around the world. The Company currently owns nine restaurant brands: Fatburger, Johnny Rockets, Buffalo’s Cafe, Buffalo’s Express, Hurricane Grill & Wings, Elevation Burger, Yalla Mediterranean and Ponderosa and Bonanza Steakhouses, and franchises approximately 700 units worldwide. For more information, please visit www.fatbrands.com.

PLBY Group Announces Successful Completion of Debt Refinancing


PLBY Group Announces Successful Completion of Debt Refinancing

 

LOS ANGELES, May 25, 2021 (GLOBE NEWSWIRE) — PLBY Group, Inc. (NASDAQ: PLBY) (“PLBY Group” or the “Company”), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, today announced the successful completion of the refinancing of their existing credit facility through a $160 million senior secured term loan maturing in May 2027.

The new term loan will accrue interest at LIBOR plus 5.75%, with a single step-down to LIBOR plus 5.25% upon achieving gross leverage of 3.0x, subject to a LIBOR floor of 0.5%. The debt refinancing is expected to result in an estimated $3 million in annual interest expense savings, reduce amortization by over $3 million annually, and eliminate over $7 million in annual excess cash flow sweep payments. The refinancing also allows the Company to request to borrow at least $30 million of additional incremental term loans, and the Company may borrow unlimited additional amounts of pari passu debt as long as its senior secured leverage ratio is below 4.75x.

“We are pleased to further strengthen our financial flexibility by refinancing our existing facility with a new term loan that should reduce our annual debt service by over $13 million and which provides a defined path for additional borrowing to fund M&A,” said Lance Barton, Chief Financial Officer of PLBY Group. “Following the strength of our first quarter results, we are well-positioned to execute on both our organic and M&A growth initiatives and build upon our incredible global brand.”

About PLBY Group, Inc.
PLBY Group connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four major categories: Sexual Wellness, Style & Apparel, Gaming & Lifestyle, and Beauty & Grooming. PLBY Group’s flagship consumer brand, Playboy, is one of the most recognizable, iconic brands in the world, driving billions of dollars in consumer spending annually across 180 countries. Learn more at http://www.plbygroup.com.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from their expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, growth plans and anticipated financial impacts of the Company’s recent business combination and its acquisitions.

These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Factors that may cause such differences include, but are not limited to: (1) the impact of COVID-19 pandemic on the Company’s business; (2) the inability to maintain the listing of the Company’s shares of common stock on Nasdaq; (3) the risk that the business combination, recent acquisitions or any proposed transactions disrupt the Company’s current plans and operations, including the risk that the Company does not complete any such proposed transactions or achieve the expected benefits from them; (4) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth profitably, and retain its key employees; (5) costs related to the business combination, acquisitions and proposed transactions; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (8) risks relating to the uncertainty of the projected financial information of the Company; (9) risks related to the organic and inorganic growth of the Company’s business and the timing of expected business milestones; and (10) other risks and uncertainties indicated from time to time in the Company’s annual report on Form 10-K, including those under “Risk Factors” therein, and in the Company’s other filings with the Securities and Exchange Commission. The Company cautions that the foregoing list of factors is not exclusive, and readers should not place undue reliance upon any forward-looking statements, which speak only as of the date which they were made. The Company does not undertake any obligation to update or revise any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

Contact:

Investors: investors@plbygroup.com
Media: press@plbygroup.com

Palladium One Drills Haukiaho Trend, Intercepts 72 Meters @ 1.8 g/t Palladium-Equivalent, Finland


Palladium One Drills Haukiaho Trend, Intercepts 72 Meters @ 1.8 g/t Palladium-Equivalent, Finland

 

May 26, 2021 – Toronto, Ontario – First drill results from the Company’s 2,000 meter drill program at Haukiaho, a zone approximately 20 kilometers south of the Company’s primary target area Kaukua South, have returned  significant widths and grades, including 72 meters at 1.8 g/t Palladium-equivalent “Pd_Eq”) (Hole LK21-071), on the Läntinen Koillismaa “LK”) PGE-Ni-Cu project in Finland, said Palladium One Mining Inc. “Palladium One” or the “Company”) (TSXV: PDM, FRA: 7N11, OTC: NKORF) today.

A total of 12 holes (1,943 metres) were drilled on the Haukiaho trend. This release contains the results from the first 7 holes of this program. The drilling was designed establish sufficient drill density to prepare a National Instrument 43-101 resource estimate at Haukiaho, which the Company anticipates completing in Q3 2021.

“Establishing a NI43-101 resource estimate at Haukiaho has been a priority for the Company given the robust historical data set available to the Company. Haukiaho was the original focus of the Phase I drill program in 2020, however, the discovery of Kaukua South led us towards first defining the potential of this new discovery and exploring the greater Kaukua area.  Despite this, Haukiaho was not forgotten and has remained an important part of our strategy to grow a multi-million ounce resource base. At 17 kilometers in length, the Haukiaho trend, currently represents the largest continuous patch of blue-sky potential on the LK property.” said Derrick Weyrauch, President and CEO.

Highlights

  • Drilling has returned significant widths and grades
  • Expanded higher grade areas within the known historic Haukiaho resource area
  • Expanded mineralization 100m to east of the historic resource
  • 72.2 meters grading 1.79 g/t Pd_Eq in hole LK21-071 starting 56m down hole, including 17.0 meters grading 2.23 g/t Pd_Eq
  • 15.7 meters grading 2.26 g/t Pd_Eq in hole LK21-069 including 3.6 meters grading 3.11 g/t Pd_Eq
  • 51.2 meters grading 1.07 g/t Pd_Eq in hole LK21-073 including 9.1 meters grading 2.10 g/t Pd_Eq
  • The historic Haukiaho resource is shallowly drilled, mostly above 200m in depth and therefore amendable to open pit mining

Haukiaho Historic Resource Estimate

In the 1980’s, Outokumpu  (a Finnish State-run mining company) prepared a resource estimate using very widely spaced holes along a portion of the Haukiaho trend, which estimated 7 million tonnes grading 0.38% Cu and 0.24% Ni, however importantly, no PGE assays were undertaken. The cut-off grade used was a 0.7% Copper_equivalent (defined as Cu% + 2 x Ni%).

Subsequently in 2013, Finore Mining Inc. completed a non-pit constrained NI43-101 historic resource estimate, over a much smaller strike length.  Using  a 0.1 g/t Pd cut-off, they estimated a resource of 1.13 million Pd_Eq ounces within 23.2 million tonnes grading 1.51 g/t Pd_Eq (0.31 g/t Pd, 0.12g/t Pt, 0.10 g/t Au, 0.21% Cu, and 0.14% Ni) (See news release August 12, 2019 and May 7, 2020).  This resource estimate encompassed widely spaced drilling with a focus on maximizing tonnage, not grade.

The Haukiaho trend is 17 kilometers long and the historic 2013 Haukiaho resource prepared by Finore covers less than 2 kilometers of this trend.  This knowledge coupled with the historic work by Outokumpu point to the enormous potential to significantly add resources at Haukiaho with disciplined execution of exploration activities.

While similar to the Kaukua deposit (See new release, September 30, 2019), the Haukiahio trend is more copper-nickel rich.  At Kaukua, approximately ~1/3 of the in-situ value per tonne is copper-nickel, while at Haukiaho copper-nickel represent approximately ~2/3s of the in-situ value.

Figure 1. LK Project location map showing 43-101 compliant Kaukua deposit and historic Haukiaho resource along with 2020 IP grids (blue lines) and current 2021 IP grid areas (black boxes). Yellow lines represent Exploration Permits, red lines represent Exploration Reservations held by the Company.

Figure 2. Plan map of Haukiaho 2020 IP chargeability anomalies and Palladium One drill holes locations.

Figure 3. Plan map of the Haukiaho historic 2013 Finore resource estimate represented by the > 0.5g/t Pd_Eq resource shape with Palladium One drill holes.

Figure 4. Haukiaho Cross section showing holes LK21-071, Finore hole HAU11-005, and geological survey of Finland (GTK) holes R-390 and R-389.

Table 1: Palladium One Haukiaho drill results

Hole

From
(m)

To
(m)

Width
(m)

Pd_Eq
g/t*

Pd
g/t

Pt
g/t

Au
g/t

Cu
%

Ni
%

LK20-008

17.3

33.5

16.2

1.99

0.38

0.15

0.14

0.26

0.20

Inc.

20.3

23.3

3.0

2.55

0.48

0.19

0.22

0.33

0.25

LK20-009

161.5

168.1

6.6

2.34

0.47

0.20

0.13

0.26

0.25

LK20-010

118.7

202.0

83.3

1.27

0.24

0.09

0.05

0.12

0.16

Inc.

166.8

201.0

34.3

2.09

0.47

0.20

0.10

0.20

0.22

Inc.

167.8

173.0

5.3

3.08

0.66

0.25

0.20

0.38

0.30

Inc.

20.3

23.3

3.0

2.55

0.48

0.19

0.22

0.33

0.25

LK21-067

No Significant values (collared in footwall rocks)

LK21-068

81.5

122.0

40.6

0.65

0.05

0.02

0.02

0.04

0.11

Inc.

106.2

120.0

13.9

0.80

0.12

0.05

0.02

0.06

0.12

Inc.

106.2

112.7

6.6

0.91

0.13

0.05

0.03

0.09

0.13

LK21-069

48.5

64.1

15.7

2.26

0.47

0.18

0.18

0.27

0.22

Inc.

48.5

60.0

11.6

2.53

0.52

0.19

0.18

0.30

0.25

Inc.

48.5

52.0

3.6

3.11

0.60

0.22

0.23

0.37

0.32

LK21-070

103.5

131.0

27.5

0.65

0.01

0.00

0.02

0.04

0.12

Inc.

113.0

119.0

6.0

0.83

0.02

0.00

0.04

0.09

0.14

LK21-071

55.8

128.0

72.2

1.79

0.37

0.15

0.14

0.22

0.17

Inc.

72.0

77.0

5.0

2.33

0.53

0.21

0.18

0.27

0.22

Inc.

74.0

75.5

1.5

3.20

0.75

0.29

0.23

0.39

0.29

And

86.2

94.0

7.8

2.74

0.53

0.21

0.23

0.32

0.27

And

111.0

128.0

17.0

2.23

0.53

0.21

0.18

0.28

0.18

Inc.

112.5

118.0

5.5

2.84

0.64

0.25

0.23

0.36

0.25

LK21-072

No Significant values (ended before zone)

LK21-073

75.8

127.0

51.2

1.07

0.15

0.06

0.06

0.13

0.13

Inc.

90.0

113.1

23.1

1.51

0.25

0.10

0.10

0.21

0.16

Inc.

90.8

99.9

9.1

2.10

0.37

0.15

0.16

0.27

0.21

Inc.

98.0

99.0

1.0

3.21

0.61

0.27

0.29

0.47

0.28

LK21-074

Pending

LK21-075

Pending

LK21-076

Pending

LK21-077

Pending

LK21-078

Pending

* Reported widths are “drilled widths” not true widths.
**Italicised orange highlighted results are previously released results see news release September 15, 2020

*Palladium Equivalent
Palladium equivalent is calculated using US$1,100 per ounce for palladium, US$950 per ounce for platinum, US$1,300 per ounce for gold, US$6,614 per tonne for copper, and US$15,4332 per tonne for nickel. This calculation is consistent with the calculation in the Company’s September 2019 NI 43-101 Kaukua resource estimate. Additionally, US$1,100 per ounce for palladium is consistent with the UBS January 2021 long-term consensus price forecast even though the current price of palladium is approximately US$2,800 per ounce.

QA/QC
The Phase I drilling program was carried out under the supervision of Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company.

Drill core samples were split using a rock saw by Company staff, with half retained in the core box and stored indoors in a secure facility, in Taivalkoski, Finland. The drill core samples were transported by courier from the Company’s core handling facility in Taivalkoski, Finland, to ALS Global “ALS”) laboratory in Outokumpu, Finland. ALS, is an accredited lab and are ISO compliant (ISO 9001:2008, ISO/IEC 17025:2005). PGE analysis was performed using a 30 grams fire assay with an ICP-MS or ICP-AES finish. Multi-element analyses, including copper and nickel were analysed by four acid digestion using 0.25 grams with an ICP-AES finish.

Certified standards, blanks and crushed duplicates are placed in the sample stream at a rate of one QA/QC sample per 10 core samples. Results are analyzed for acceptance at the time of import. All standards associated with the results in this press release were determined to be acceptable within the defined limits of the standard used.

Qualified Person
The technical information in this release has been reviewed and verified by Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company and the Qualified Person as defined by National Instrument 43-101.

About Palladium One
Palladium One Mining Inc. is an exploration company targeting district scale, platinum-group-element (PGE)-copper nickel deposits in Finland and Canada. Its flagship project is the Läntinen Koillismaa or LK Project, a palladium dominant platinum group element-copper-nickel project in north-central Finland, ranked by the Fraser Institute as one of the world’s top countries for mineral exploration and development. Exploration at LK is focused on targeting disseminated sulfides along 38 kilometers of favorable basal contact and building on an established NI 43-101 open pit resource.

ON BEHALF OF THE BOARD
“Derrick Weyrauch”
President & CEO, Director

For further information contact: Derrick Weyrauch, President & CEO
Email: info@palladiumoneinc.com

Neither the TSX Venture Exchange nor its Market Regulator (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release includes “forward-looking information” that is subject to a few assumptions, risks and uncertainties, many of which are beyond the control of the Company. Statements regarding listing of the Company’s common shares on the TSXV are subject to all of the risks and uncertainties normally incident to such events. Investors are cautioned that any such statements are not guarantees of future events and that actual events or developments may differ materially from those projected in the forward-looking statements. Such forward-looking statements represent management’s best judgment based on information currently available. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions and general business conditions. Such forward-looking information reflects the Company’s views with respect to future events and is subject to risks, uncertainties and assumptions, including those set out in the Company’s annual information form dated April 29, 2020 and filed under the Company’s profile on SEDAR at www.sedar.com. The Company does not undertake to update forward?looking statements or forward?looking information, except as required by law. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements.

ProMIS Neurosciences initiates commercialization of COVID-19 serology assay


ProMIS Neurosciences initiates commercialization of COVID-19 serology assay

 

Seasoned industry executive and entrepreneur, Owen Dempsey to lead the effort for ProMIS

TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 25, 2021– ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that it has initiated commercialization of its COVID-19 serology assay and has appointed Owen Dempsey to lead the commercialization program.

Owen’s professional work for the past 25 years has been to build companies founded to discover and commercialize antibodies in applications including life science research, pharmaceutical drug discovery, clinical diagnostics and therapeutic treatment of cancer, AIDS and other serious illness.  He has led private, venture-backed as well as NASDAQ-listed companies and is a past board member of ALDA, the Analytical, Life Science & Diagnostics Association.

 “I am delighted to lead this opportunity on behalf of ProMIS Neurosciences”, stated Owen Dempsey. “Our serology assay commercialization efforts will be targeting the need for a highly accurate test to detect, quantify and characterize antibodies against the virus causing COVID-19, either as a consequence of contracting the viral disease or in response to vaccination. Our initial focus will be on commercialization to the medical and public health community, vaccine developers, pharmaceutical companies, governmental agencies and other organizations.”

This advanced serology test developed by ProMIS Neurosciences measures not only serum antibodies to SARS-CoV-2, the novel coronavirus causing COVID-19, but also their protective activity against infection.  The assay simultaneously assesses antibody levels in the blood of study participants and their neutralizing activity against the original strain of SARS-CoV-2 as well as emerging variants.  Additional variants can be added to the assay as they are identified.  The assay utilizes an advanced, high-throughput, sensitive and accurate surface plasmon resonance (SPR) technology as opposed to traditional ELISA (enzyme-linked immunosorbent assay) methods.  

In commercializing an advanced serology testing platform, we aim to meet the needs of the medical community and investigators in academia, industry and government working to assess response and durability of response to vaccines as well as to monitor and assess antibody response to emerging strains of the virus..  As reported in the scientific literature, our accurate and sensitive format is capable of measuring neutralizing antibodies that inhibit coronavirus RBD binding to the human ACE2 receptor. This provides a powerful surrogate measure of antibody immunity without the need for live virus or pseudovirus formats. This and similar collaborative efforts may help to guide the need for boosters or modified vaccines addressing emerging strains and will inform the medical community’s preparedness to meet similar public threats to global health in the years ahead. 

It is important to note, as stated above that the initial marketing and commercialization of the assay will be directed only to organizations such as vaccine manufacturers, pharmaceutical companies and government organizations at the national and state/provincial level. The assay is not currently available to private individual consumers or the general public.

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

 

For further information about ProMIS Neurosciences, please consult the Company’s website at:  www.promisneurosciences.com

 

Follow us on Twitter

Like us on LinkedIn

 

For Investor Relations please contact:

Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785

 

 

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. Specifically, the Company’s effort to commercialize its COVID-19 serology assay may not succeed due to many known and unknown factors, including the emergence of competing products, lack of market acceptance for its test, the cost of production relative to the revenue generated, and/or changes in the need for COVID-19 serology tests. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.